$185 Million is the total value of Stonepine Capital Management, LLC's 29 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 95.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMYT | Buy | AMRYT PHARMA LTDsponsored ads | $35,156,000 | +75.3% | 2,523,728 | +78.2% | 18.99% | +23.7% |
| ADMS | Buy | ADAMAS PHARMACEUTICALS INC | $16,408,000 | +368.7% | 3,418,279 | +322.8% | 8.86% | +230.7% |
| CHMA | Buy | CHIASMA INC | $15,463,000 | +392.8% | 4,940,273 | +584.9% | 8.35% | +247.8% |
| CBIO | Buy | CATALYST BIOSCIENCES INC | $12,349,000 | +134.5% | 2,450,193 | +193.6% | 6.67% | +65.5% |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $10,849,000 | – | 422,310 | +100.0% | 5.86% | – |
| OVID | New | OVID THERAPEUTICS INC | $9,982,000 | – | 2,483,059 | +100.0% | 5.39% | – |
| CTIC | Buy | CTI BIOPHARMA CORP | $9,584,000 | +44.9% | 3,293,419 | +60.3% | 5.18% | +2.3% |
| DMAC | Buy | DIAMEDICA THERAPEUTICS INC | $9,364,000 | -2.8% | 1,023,409 | +7.7% | 5.06% | -31.4% |
| AFMD | Buy | AFFIMED NV | $8,147,000 | +538.0% | 1,030,004 | +369.6% | 4.40% | +350.0% |
| APEN | Sell | APOLLO ENDOSURGERY INC | $7,983,000 | +0.9% | 1,448,868 | -37.7% | 4.31% | -28.8% |
| XOMA | Buy | XOMA CORP | $6,663,000 | +21.6% | 163,266 | +31.5% | 3.60% | -14.2% |
| YMTX | Buy | YUMANITY THERAPEUTICS INC | $6,077,000 | +228.5% | 335,745 | +208.5% | 3.28% | +131.9% |
| ISEE | Buy | IVERIC BIO INC | $5,409,000 | -2.2% | 875,180 | +9.4% | 2.92% | -31.0% |
| PLXP | New | PLX PHARMA INC | $4,572,000 | – | 506,274 | +100.0% | 2.47% | – |
| CFMS | New | CONFORMIS INC | $4,387,000 | – | 4,431,807 | +100.0% | 2.37% | – |
| EYPT | New | EYEPOINT PHARMACEUTICALS INC | $3,344,000 | – | 329,130 | +100.0% | 1.81% | – |
| XGN | New | EXAGEN INC | $3,343,000 | – | 191,006 | +100.0% | 1.81% | – |
| AYTU | Sell | AYTU BIOPHARMA INC | $2,758,000 | -67.0% | 362,910 | -74.1% | 1.49% | -76.7% |
| ANGN | New | ANGION BIOMEDICA CORP | $2,439,000 | – | 134,984 | +100.0% | 1.32% | – |
| GMDA | Sell | GAMIDA CELL LTD | $1,978,000 | -37.9% | 244,515 | -35.6% | 1.07% | -56.2% |
| CELC | New | CELCUITY INC | $1,564,000 | – | 109,081 | +100.0% | 0.84% | – |
| CFRX | New | CONTRAFECT CORP | $1,292,000 | – | 269,101 | +100.0% | 0.70% | – |
| SBBP | Sell | STRONGBRIDGE BIOPHARMA PLC | $1,230,000 | -62.5% | 445,701 | -67.0% | 0.66% | -73.6% |
| APVO | Buy | APTEVO THERAPEUTICS INC | $1,178,000 | +75.8% | 38,593 | +111.1% | 0.64% | +24.0% |
| CRVS | New | CORVUS PHARMACEUTICALS INC | $974,000 | – | 316,279 | +100.0% | 0.53% | – |
| AGTC | New | APPLIED GENETIC TECHNOLOGIES | $910,000 | – | 179,511 | +100.0% | 0.49% | – |
| GLPG | New | GALAPAGOS NVspon adr | $771,000 | – | 10,000 | +100.0% | 0.42% | – |
| BWAY | New | BRAINSWAY LTDsponsored ads | $498,000 | – | 55,181 | +100.0% | 0.27% | – |
| ONCS | New | ONCOSEC MEDICAL INC | $452,000 | – | 94,783 | +100.0% | 0.24% | – |
| CPIX | Exit | CUMBERLAND PHARMACEUTICALS | $0 | – | -188,703 | -100.0% | -0.43% | – |
| VTGN | Exit | VISTAGEN THERAPEUTICS INC | $0 | – | -500,000 | -100.0% | -0.74% | – |
| NVUS | Exit | NOVUS THERAPEUTICS INC | $0 | – | -167,333 | -100.0% | -1.97% | – |
| NEOS | Exit | NEOS THERAPEUTICS INC | $0 | – | -4,962,657 | -100.0% | -2.37% | – |
| SCYX | Exit | SCYNEXIS INC | $0 | – | -685,000 | -100.0% | -4.01% | – |
| LGND | Exit | LIGAND PHARMACEUTICALS | $0 | – | -326,100 | -100.0% | -24.83% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.